Jho Low is helping fund a health care revolution.
Low, a frequent visitor to the Houston area for ongoing business and philanthropic initiatives, learned firsthand about the importance of access to the institution’s cancer knowledge and expertise.
“Early in 2013, my grandfather was living in Malaysia and was diagnosed with acute myeloid leukemia,” says Low, co-director of the Jynwel Charitable Foundation, which seeks to fund breakthrough programs that are working to solve the toughest problems in global health, education and conservation. “Fortunately, my family was able to connect halfway around the world with MD Anderson’s Dr. Hagop Kantarjian, who consulted with my grandfather’s local physicians and guided his care.”
The CEO of the global investment firm Jynwel Capital has committed an extraordinary $50 million through the Jynwel Charitable Foundation to the Moon Shots Program. Low’s generous gift supports the development of MD Anderson’s Oncology Expert Advisor™ (OEA), powered by IBM’s Watson, a clinical-decision support tool that ingests, analyzes and organizes vast amounts of data to help physicians determine the most promising treatments for each patient. It’s a key component of the program’s adaptive learning environment dubbed APOLLO (Adaptive Patient Oriented Longitudinal Learning and Optimization), whose pilot project is MD Anderson’s Leukemia department.
In time, it’s believed that the OEA can optimize patient care, speed new discoveries and allow doctors throughout Texas, the U.S. and around the globe to tap into MD Anderson’s superior level of cancer care expertise.
“MD Anderson’s innovative partnership with IBM to apply the Watson technology to important health care challenges is a tremendous step in the global fight against cancer,” Low says. “The OEA can potentially provide patients around the world with access to the best possible cancer care. I'm proud, and humbled, to lend my support to this game-changing effort.”